Bruker Corporation (BRKR) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Bruker published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Bruker reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Effective July 1, 2026 Bruker reorganized its reportable segments into BSI BIOS, BSI Microbiology and Infection Diagnostics (BMID), BSI NANO and BEST, replacing BioSpin, CALID and NANO. Prior periods were recast.
• GAAP results include a non-cash goodwill impairment charge of $174.5 million in the BSI NANO segment, the remaining goodwill of the Bruker Spatial Biology and Cellular Analysis reporting unit.

Source: Bruker Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Bruker splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Bruker's Bruker Scientific Instruments (BSI) revenue was $794 million in Q3 2026, up 1% from $788 million in Q3 2025, 91% of total revenue.
• Bruker's BEST revenue was $82.1 million in Q3 2026, up 11% from $73.8 million in Q3 2025, 9% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Bruker said:

“Bruker now expects FY26 revenues of $3.52 to $3.56 billion, compared to FY25 revenues of $3.44 billion, with 2.5% to 3.5% year-over-year reported revenue growth”

“Organic revenue growth of 1% to 2%”

“Foreign currency neutral to revenue (previously a tailwind of 0.5%)”

“Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year.”

Source: Bruker Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the BRKR forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS (net income or loss per share attributable to common shareholders), each as first reported in that quarter's release.

We do not hold a confirmed date for Bruker's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Bruker sells scientific instruments and diagnostic systems through Bruker Scientific Instruments (BSI), which brought in $793.9 million of Bruker's $874.0 million of revenue in Q3 2026. Since July 1, 2026 BSI has been split into BIOS ($397.2 million), MID ($133.6 million) and Nano ($263.1 million). The fourth segment, BEST, which makes superconducting wire for MRI, NMR and fusion research magnets, had revenue of $82.1 million. (Bruker Q3 2026 release, Nov 4, 2026; Bruker Form 10-K, 2025, Feb 27, 2026)

Bruker's revenue rose 1.6% from $860.5 million. Acquisitions added 1.7% and currency translation subtracted 0.8%, leaving organic growth of 0.7%. BSI revenue grew 0.8% but fell 0.4% organically, while BEST grew 11.2%, with organic growth of 11.8%. (Bruker Q3 2026 release, Nov 4, 2026)

The 10-Q credits most of Bruker's growth to BSI BIOS and BEST. BIOS gained a $14.0 million, or 3.5%, contribution from acquisitions, primarily Tofwerk and Mimetas, and higher demand in industrial and semiconductor markets, partly offset by lower revenue from hospital and clinical customers and the academic and government research market. BEST grew on demand from the hospital and clinical market. (Bruker Form 10-Q, Q3 2026, Nov 5, 2026)

By end customer geography, Europe was Bruker's largest region at $320.2 million, followed by Asia Pacific at $247.7 million, the United States at $231.2 million and other regions at $74.9 million. Asia Pacific was the only region lower than a year earlier, down from $252.5 million. No single customer accounted for more than 10% of revenue in any of the three years through 2025. (Bruker Q3 2026 release, Nov 4, 2026; Bruker Form 10-K, 2025, Feb 27, 2026)

Bruker reported a GAAP diluted loss of $0.81 per share in Q3 2026 and non-GAAP diluted EPS of $0.56, up 24.4% from $0.45. Total non-GAAP adjustments came to $1.37 per share, led by the $174.5 million goodwill impairment ($1.14 per share), $30.1 million of purchased intangibles amortization ($0.20), $35.8 million of investments-related adjustments ($0.23) and $20.0 million of acquisition-related costs ($0.12), less a $51.8 million tax effect. (Bruker Q3 2026 release, Nov 4, 2026)

The impairment wrote off the remaining goodwill of the Bruker Spatial Biology and Cellular Analysis reporting unit in the BSI NANO segment, after shifts in competition and operating results below expectations led Bruker to lower its long-term forecasts. Including a $36.5 million charge in Q2, goodwill impairments for that unit totaled $211.0 million in the first nine months of 2026. (Bruker Form 10-Q, Q3 2026, Nov 5, 2026)

Bruker's per-share loss also reflects $11.0 million of dividends on its Series A Mandatory Convertible Preferred Stock, issued in Q3 2025, which brought the net loss attributable to common shareholders to $122.8 million. The GAAP effective tax rate was 10.1%, against 19.6% a year earlier, and the non-GAAP tax rate was 28.4%. Diluted shares were 152.5 million, and the preferred stock was anti-dilutive. (Bruker Q3 2026 release, Nov 4, 2026; Bruker Form 10-Q, Q3 2026, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Bruker gives a full-year outlook in its release. With Q3 2026 it lowered its FY26 revenue range to $3.52 billion to $3.56 billion because foreign currency is now neutral to revenue, previously a tailwind of 0.5%, and kept organic revenue growth at 1% to 2%, with M&A adding approximately 1.5%. It kept non-GAAP EPS guidance of $2.10 to $2.15, against $1.83 in FY25. (Bruker Q3 2026 release, Nov 4, 2026)

Bruker's chief executive said in the release that BSI organic bookings and backlog were both up mid-single digits % year-to-date and that Bruker expects revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27. Bruker does not reconcile its non-GAAP outlook to GAAP. (Bruker Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Bruker, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Bruker's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BRKR is on is BRKR a buy or a sell?, what analysts expect next is on the BRKR forecast, and what the company does is on the Bruker Corporation (BRKR) stock page.

Every number on this page can be traced to a document Bruker published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.